In re Solodyn Antitrust Litigation – Antitrust Class Action Settlement

Berger Montague served as co-lead counsel and obtained over $76.8 million in total settlements on behalf of a class of direct purchasers of brand and generic Solodyn (extended-release minocycline hydrochloride tablets) in this antitrust action. Led by David F. Sorensen, Caitlin G. Coslett, and Andrew C. Curley, the plaintiffs alleged that Medicis Pharmaceutical Corp. entered into agreements with each of Impax Laboratories, Inc., Sandoz Inc., and Lupin Limited/Lupin Pharmaceuticals, Inc. not to compete in the market for extended-release minocycline hydrochloride tablets, including Solodyn and its generic equivalents, in violation of the Sherman Act, resulting in the class paying overcharge damages.

After more than four years of litigation and on the eve of trial, the direct purchaser class settled with the last remaining defendant, Impax Laboratories, Inc. In total, the class received more than $76.8 million in settlements. The case was litigated in the United States District Court for the District of Massachusetts and captioned In re Solodyn Antitrust Litigation, No. 14-MD-2503-DJC (D. Mass.).

If you or your company has been harmed by anticompetitive conduct or any conduct that you believe violates the antitrust laws, please contact Berger Montague.

About Berger Montague

Berger Montague is a national law firm focusing on complex civil litigation in federal and state courts throughout the United States. For over half a century, Berger Montague has played lead roles in consequential, precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago, Minneapolis, San Diego, San Francisco, Toronto, and Washington, D.C.